RxDoctor Payments Data

Rodrigo Fernandez, MD

Nephrology · Chula Vista, CANPI 1366539793

Payments from drug & device makers

$8,415in general payments, 2019–2025

Across 361 payments — averaging $23.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • OPKO Pharmaceuticals, LLC$926
  • Amgen$592
  • GSK$531
  • Bayer$522
  • Novartis$443
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$8,15697%
  • Education$2603%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,415 in reported general payments places this provider in the 75th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$67,415
Medicare patients
63
Services billed
275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol105$98,641
TrulicityDulaglutide60$88,838
TradjentaLinagliptin61$65,269
RayaldeeCalcifediol57$54,319
JardianceEmpagliflozin47$40,999
EliquisApixaban24$36,991
OzempicSemaglutide31$35,813
EntrestoSacubitril/Valsartan27$31,980
Diclofenac Sodium30$31,214
KerendiaFinerenone29$24,517
LokelmaSodium Zirconium Cyclosilicate25$16,920
VeltassaPatiromer Calcium Sorbitex20$14,287
JanuviaSitagliptin Phosphate25$14,243
JanumetSitagliptin Phos/Metformin Hcl16$13,793
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$11,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$1,627$115,561130 claims
Boehringer IngelheimTradjenta, Jardiance$254$106,269108 claims
Lilly USA, LLCTrulicity$375$88,83860 claims
OPKO Pharmaceuticals, LLCRayaldee$926$54,31957 claims
PfizerEliquis$48$36,99124 claims
Novo NordiskOzempic$298$35,81331 claims
NovartisEntresto$443$31,98027 claims
MerckJanuvia, Janumet$23$28,03641 claims
BayerKerendia$522$24,51729 claims
GSKTrelegy Ellipta$531$11,52815 claims
Johnson & JohnsonProcrit$30$10,09520 claims
Sanofi-aventis U.S. LLCLantus$11$4,45829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,341 nephrology providers in California.

Other nephrology in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →